Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
globenewswire.com
news
2022-10-19 00:00:00

English Icelandic Expanded partnership covers biosimilar candidates in immunology and oncology Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and the JAMP Pharma Group (JAMP Pharma), a Canadian owned pharmaceutical company headquartered in the Montreal area, announced today that the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding two biosimilar candidates from Alvotech's pipeline: AVT16 a biosimilar for an immunology product and AVT33, a biosimilar for Â an oncology product.
